Clinical Trials Logo

Recurrent Respiratory Papillomatosis clinical trials

View clinical trials related to Recurrent Respiratory Papillomatosis.

Filter by:

NCT ID: NCT02859454 Recruiting - Clinical trials for Human Papilloma Virus

Avelumab for People With Recurrent Respiratory Papillomatosis

Start date: August 6, 2016
Phase: Phase 2
Study type: Interventional

Background: Recurrent respiratory papillomatosis (RRP) is a rare disease caused by human papillomavirus. It can cause voice changes, airway compromise, pulmonary lesions, and cancers. PD-L1 is a protein on cells. It may be able to stop or decrease the immune system s response to viruses such as human papillomavirus. The drug Avelumab interferes with the activity of PD-L1. Researchers want to see if Avelumab treats RRP and study its side effects. Objective: To see if Avelumab works in treating RRP and is safe. Eligibility: People ages 18 and older with aggressive RRP that has not responded to available treatments Design: Participants will be screened with: Medical history Previously collected tumor tissue Physical exam Blood, urine, and heart tests Endoscopy procedure: A small tube with a camera is used to look in the nose, throat, larynx, and upper windpipe. Before starting treatment, participants will have: Endoscopy under anesthesia. A sample of papilloma will be taken. Voice handicap questionnaire CT scans Apheresis: An IV is inserted into an arm vein. White blood cells are separated from the rest of the blood and stored for research. The rest of the blood is returned through the same IV or one in the other arm. Participants will get the study drug by IV every 2 weeks for up to 12 weeks. Participants will repeat the previous tests throughout the study. If they respond to treatment, participants will be evaluated every 6 weeks (3 times), then every 12 weeks (3 times), then every 26 weeks (2 times) until their disease progresses. Participants will be evaluated 30 days after their last infusion. They will then be contacted annually.

NCT ID: NCT02854761 Not yet recruiting - Clinical trials for Recurrent Respiratory Papillomatosis

Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)

Start date: September 2016
Phase: Phase 1
Study type: Interventional

This study evaluates the safety and tolerability of the investigational drug EF-022 in the treatment of adult patients with Recurrent Respiratory Papillomatosis (RRP). Patients will be administered EF-022, either intramuscular or subcutaneous, for a period of 6 months. Preliminary effect of the drug on the disease will be evaluated by following the number and severity of the lesions in the respiratory tract and the effect on voice changes.

NCT ID: NCT02632344 Recruiting - Clinical trials for Recurrent Respiratory Papillomatosis

Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement

Start date: April 2016
Phase: Phase 2
Study type: Interventional

This research study is evaluating an immune modulatory agent as a possible treatment for patients with Recurrent Respiratory Papillomatosis (RRP) with significant disease involving the larynx, trachea, and/or lungs. The investigators will be using Pembrolizumab as the treating agent.

NCT ID: NCT02592902 Recruiting - Clinical trials for Recurrent Respiratory Papillomatosis

Recurrent Respiratory Papillomatosis and Extraesophageal Reflux

Start date: April 2014
Phase: N/A
Study type: Interventional

The purpose of the study was to determine, whether patients with recurrent respiratory papillomatosis (RRP) suffer from extra oesophageal reflux more often than patients with laryngeal cyst (control group).

NCT ID: NCT02555800 Recruiting - Clinical trials for Recurrent Respiratory Papillomatosis

Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis

Start date: December 2014
Phase: Phase 2
Study type: Interventional

The aim of this study is to compare the efficacy of intralesional bevacizumab, a monoclonal antibody against vascular endothelial growth factor, versus the antiviral drug cidofovir in patients with recurrent respiratory papillomatosis.

NCT ID: NCT02217358 Completed - Clinical trials for Recurrent Respiratory Papillomatosis

Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions

Start date: February 2012
Phase: N/A
Study type: Interventional

The aim of the project is to compare NBI endoscopy and standard endoscopic method using white light and evaluate accuracy both methods in early detection and diagnosis hypopharyngeal and laryngeal precancerous and cancerous lesions. A higher contrast between the mucosal epithelium and blood vessels is achieved in NBI endoscopy using filtered light comparing to white light observations. This allows detection of small mucosal changes, few millimetres in diameter, which are not observable using white light. The second aim in patients with squamous cell carcinoma of the upper aerodigestive tract is to compare extension of mucosal lesions by evaluation of NBI endoscopy and white light endoscopy, which is crucial for perform targeted biopsy and for determination of resection margins in cancer surgery. The investigators expect that dysplastic changes of mucosa or early laryngeal cancerous lesions are detected in white light endoscopy rarely. In case our hypothesis is confirmed, frequency of precancerous and early cancerous lesions of hypopharynx and larynx is more common in patients with non-specific symptoms of laryngeal and pharyngeal diseases.

NCT ID: NCT01995721 Not yet recruiting - Clinical trials for Recurrent Respiratory Papillomatosis

4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children

Start date: February 2014
Phase: Phase 3
Study type: Interventional

Recurrent respiratory papillomatosis in children caused by HPV 6,11 can be a life threatening condition resulting in surgical interventions. The maturing and disintegrating papillomas are the sources for the subsequent HPV relapses and immunization might slow down or even prevent this ongoing process. After an initial immunological and ear-nose-throat (ENT) assessment children with at least 3 relapses in their patient history will be vaccinated with 4-valent HPV vaccine according to the following schedule: 0., 2., 6. months. It will be followed by an immunological and 3 ENT examinations to assess response to vaccination.

NCT ID: NCT01058317 Withdrawn - Clinical trials for Recurrent Respiratory Papillomatosis

Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis

Start date: January 2010
Phase: Phase 2/Phase 3
Study type: Interventional

Juvenile onset recurrent respiratory papillomatosis (JORRP) is a rare, difficult to treat, benign tumor of the pediatric airway. Current therapy is mainly surgical, but in a significant portion of patients adjuvant therapy is required to control the disease process. Although multiple adjuvant medical therapies have been tried, success has been limited. We have seen some success in a limited amount of patients using orally administered propranolol. Our goal is to enroll a larger cohort of patients to determine the effectiveness of propranolol as an adjuvant therapy for JORRP.

NCT ID: NCT01020747 Completed - Clinical trials for Recurrent Respiratory Papillomatosis

Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)

Start date: November 2009
Phase: Phase 1
Study type: Interventional

This phase I single center open labeled study is planned to assess the safety and tolerability of bevacizumab for treating patients with bilateral Recurrent Respiratory Papillomatosis (RRP). Approximately 20 patients will receive bevacizumab directly injected into the vocal folds. Patients who enroll in the protocol will be injected with bevacizumab in one vocal fold that represents the more diseased of the two folds. A sham injection with saline will be administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection. The investigator will also treat lesions by laser photoangiolysis of both vocal folds using the 532 nm potassium-titanyl-phosphate (KTP) laser.

NCT ID: NCT00829608 Withdrawn - Clinical trials for Recurrent Respiratory Papillomatosis

Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis

Start date: January 2009
Phase: Phase 0
Study type: Interventional

The purpose of this study is to determine if administration of the HPV quadrivalent vaccine in patients diagnosed with RRP has a therapeutic effect on their clinical course. More specifically, does administration of the vaccine decrease the size and number of papillomas, severity of disease (i.e. hoarseness, inspiratory vs. biphasic stridor, airway obstruction) using the LCAS and time interval between required surgical debulking will be analyzed.